비교리스트

 카트 문의
시장보고서
상품코드
1656901

세계의 프리필드시린지 시장 : 인사이트, 경쟁 환경, 시장 예측(-2032년)

Prefilled Syringes - Market Insights, Competitive Landscape, and Market Forecast - 2032
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

프리필드 시린지 시장 규모는 2024년에 124억 9,079만 달러로 평가되었습니다. 이 시장은 2025년부터 2032년까지 예측 기간 동안 10.73%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 279억 9,335만 달러에 달할 것으로 예상됩니다. 세계 프리필드 시린지 시장은 만성 질환 증가, 생물학적 제제 및 바이오시밀러의 사용 증가, 자가 투여의 채택으로 인해 성장하고 있습니다. 당뇨병이나 류마티스 관절염과 같은 만성 질환은 지속적인 주사 치료가 필요하며, 프리필드시린지는 환자에게 안전하고 편리한 치료 관리 방법을 제공합니다. 암이나 자가면역질환과 같은 복잡한 질환에 대한 생물학적 제제 및 바이오시밀러의 사용은 사용하기 쉬운 주사 시스템에 대한 수요를 더욱 증가시키고 있습니다. 또한, 집에서 자가 투약하는 방식으로의 전환은 편의성을 높여 프리필드시린지의 전체 수요를 증가시키고 있습니다. 이러한 요인들을 종합하면 2025년부터 2032년까지 예측 기간 동안 프리필드시린지는 강력한 성장 궤도를 그릴 것으로 예상됩니다.

세계보건기구(WHO)의 최근 데이터(2023년)에 따르면, 전 세계적으로 약 5억 2,800만 명이 골관절염을 앓고 있습니다.

또한, Institute for Health Metrics and Evaluation에서 제공한 최근 데이터(2023년)에 따르면 2050년까지 약 10억 명이 골관절염에 걸릴 것으로 예측되며, 가장 많이 걸리는 부위는 무릎과 허리입니다. 구체적으로 무릎 골관절염은 74.9%, 손목 골관절염은 48.6%, 고관절 골관절염은 78.6%, 팔꿈치, 어깨 등 기타 부위의 골관절염은 95.1% 증가할 것으로 예측되고 있습니다.

골관절염 환자들은 통증 완화 및 관절 운동성을 위해 히알루론산이나 코르티코스테로이드 주사를 필요로 하는 경우가 많습니다. 프리필드시린지는 이러한 치료를 임상 및 가정에서 편리하고 무균적인 방법으로 제공함으로써 전 세계 프리필드시린지 시장을 견인하고 있습니다. 예를 들어, 사노피의 자회사인 Genzyme Corporation의 Synvisc-One(R)은 무릎 관절의 윤활과 쿠션을 도와 최대 6개월 동안 골관절염의 통증을 완화하는 프리필드시린지입니다.

또한 세계보건기구(WHO)의 최근 자료(2023년)에 따르면 전 세계적으로 180만 명 이상이 다발성경화증에 걸린 것으로 보고되고 있습니다. 다발성 경화증은 면역체계가 뇌와 척수를 잘못 공격하여 인지, 감정, 운동, 감각, 시각 능력 등 다양한 기능에 영향을 미칩니다. 프리필드시린지는 바로 사용할 수 있고 정확하고 사용하기 쉬운 전달 시스템을 제공함으로써 투여를 단순화하고, 투약 오류를 줄이며, 환자의 치료 요법 순응도를 높이기 때문에 이 증상을 관리하는 데 매우 중요한 역할을 합니다. 예를 들어, AVONEX는 재발성 다발성 경화증에 대한 주 1회 치료제로 30mcg의 근육 내 프리필드시린지 형태로 제공됩니다.

또한, 단클론 항체, 성장인자, 백신과 같은 생물학적 제제는 암이나 자가면역질환과 같은 만성질환의 치료에 필수적입니다. 주사로 투여되는 프리필드 시린지는 편리하고 정확한 전달 방법을 제공합니다. 또한, 생물학적 제제의 바이오시밀러 및 제네릭의 등장으로 프리필드시린지에 대한 수요가 더욱 증가하여 보다 저렴한 치료 옵션을 제공합니다.

세계의 프리필드시린지(Prefilled Syringes) 시장에 대해 조사했으며, 시장 개요와 함께 제품 유형별, 재료별, 유형별, 유통 채널별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 전해드립니다.

목차

제1장 프리필드 시린지 시장 보고서 서론

제2장 프리필드 시린지 시장 주요 요약

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 프리필드 시린지 시장의 주요 요인 분석

  • 프리필드 시린지 시장 성장 촉진요인
  • 프리필드 시린지 시장 성장 억제요인과 과제
  • 프리필드 시린지 시장 기회

제6장 프리필드 시린지 시장 : Porter의 Five Forces 분석

제7장 프리필드 시린지 시장 평가

  • 제품 유형별
    • Staked Needle System
    • Luer Cone System
    • Luer Lock System
  • 소재별
    • 유리
    • 플라스틱
  • 유형별
    • 바늘 있음
    • 바늘 없음
  • 유통 채널별
    • 병원 및 약국
    • 온라인 약국
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 프리필드 시린지 시장 기업과 제품 개요

  • BD
  • Nipro Corporation
  • Taisei Kako Co., Ltd.
  • Terumo Corporation
  • SCHOTT Pharma AG & Co. KGaA
  • Gerresheimer AG
  • Johnson and Johnson Services, Inc.
  • Dali Medical Devices
  • Stevanato Groupand
  • Credence MedSystems, Inc.
  • Baxter
  • MAEDA INDUSTRY Co., Ltd.
  • MedXL, Inc.
  • Sanofi
  • Sandoz AG
  • Pfizer Inc.
  • B. Braun Melsungen AG
  • Novartis AG
  • Fresenius SE & Co. KGaA
  • Cardinal Health

제9장 KOL(Key Opinion Leader)의 견해

제10장 프로젝트 접근

제11장 DelveInsight에 대해

제12장 면책사항과 문의

LSH 25.03.06

Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic diseases, increase impact of biologics and biosimilar on prefilled syringes, increase adoption of self-administration across the globe.

The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032. The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes during the forecast period from 2025 to 2032.

Prefilled Syringes Market Dynamics:

According to the recent data provided by the World Heart Organization (2023), about 528 million people globally were living with osteoarthritis.

Additionally, according to the recent data provided by the Institute for Health Metrics and Evaluation (2023), by 2050, nearly one billion people are projected to have osteoarthritis, with the most common areas affected being the knees and hips. Specifically, osteoarthritis of the knee is expected to increase by 74.9%, osteoarthritis of the hand by 48.6%, osteoarthritis of the hip by 78.6%, and osteoarthritis in other areas, such as the elbow and shoulder, by 95.1%.

Patients with osteoarthritis often need hyaluronic acid or corticosteroid injections for pain relief and joint mobility. Prefilled syringes provide a convenient and sterile method for administering these treatments in clinical and home settings, thus boosting the global prefilled syringe market. For example, Synvisc-One(R) manufactured by Genzyme Corporation, which is a subsidiary of Sanofi is a prefilled syringe that helps lubricate and cushion the knee joint, offering relief from osteoarthritis pain for up to six months.

Additionally, as per recent data from the World Health Organization (2023), it was reported that over 1.8 million people worldwide were affected by multiple sclerosis. Multiple sclerosis impacted various functions, including cognitive, emotional, motor, sensory, and visual abilities, as the immune system mistakenly attacked the brain and spinal cord. Prefilled syringes were crucial for managing the condition, as they simplified dosing, reduced medication errors, and enhanced patient adherence to treatment regimens by offering a ready-to-use, accurate, and user-friendly delivery system. For instance, AVONEX is a once-weekly treatment for relapsing multiple sclerosis, provided as a 30 mcg intramuscular prefilled self-syringe.

Moreover, Biologics, including monoclonal antibodies, growth factors, and vaccines, are crucial for treating chronic conditions like cancer and autoimmune diseases. Administered via injection, prefilled syringes offer a convenient and accurate delivery method. Additionally, the rise of biosimilar generic versions of biologics has further propelled the demand for prefilled syringes, providing a more affordable treatment option.

For instance, in July 2024, Sandoz Group AG, a global leader in generic and biosimilar medicines, announced that the U.S. Food and Drug Administration (FDA) approved its biosimilar Pyzchiva(R)* (ustekinumab-ttwe) in 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection, as well as a 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion.

Thus, the factors mentioned above are expected to boost the overall market of prefilled syringes across the globe during the forecast period from 2025 to 2032.

However, increasing product recalls and failures due to safety issues and the availability of alternative products may hinder the future market of prefilled syringes across the globe during the forecasted period.

Prefilled Syringes Market Segment Analysis:

Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The staked needle system category in the prefilled syringes market is estimated to dominate the market with a market share of 68.37% in 2024. The adoption of staked needle systems is significantly boosting the overall market of prefilled syringes by addressing key challenges in drug delivery and enhancing the usability, safety, and efficiency of injectable therapies. A staked needle system integrates the needle directly into the syringe barrel, eliminating the need for additional assembly, such as attaching a separate needle. This design simplifies the injection process, reduces preparation time, and minimizes the risk of needle-related complications, such as detachment or improper attachment, making it highly preferred in both clinical and self-administration settings.

One of the major drivers of the staked needle system's impact is its contribution to patient safety. The fixed-needle design reduces the risk of needle-stick injuries, which is a critical concern for healthcare professionals, especially in high-pressure environments like hospitals and emergency care. Additionally, the reduced dead space in staked needle systems ensures precise dosing and minimizes medication waste, which is particularly advantageous for high-cost biologics, vaccines, and specialty drugs. This attribute makes staked needle systems an ideal choice for administering small-volume, high-potency medications, aligning with the growing demand for precision medicine. The integration of staked needle systems into advanced prefilled syringes, such as autoinjectors and pen injectors, further boosts their appeal in the rapidly growing self-injection device market.

Pharmaceutical companies are increasingly adopting staked needle systems for their prefilled syringes due to their compatibility with a wide range of drugs, including biologics and biosimilars, which are gaining traction globally. The design ensures the sterility and integrity of the drug product, reducing the likelihood of contamination or degradation. Furthermore, staked needle systems are well-suited for high-speed, automated manufacturing processes, enabling efficient large-scale production while maintaining consistent quality, which aligns with the rising demand for prefilled syringes worldwide.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of prefilled syringes across the globe.

North America is expected to dominate the overall prefilled syringes market:

Among all regions, North America is estimated to hold the largest share of 34% in the global prefilled syringes market in 2024, growing at a CAGR of 11.02% during the forecast period from 2025 to 2032. This can be attributed to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of prefilled syringes across the region.

According to data provided by the Centers for Disease Control and Prevention (CDC) in 2023, it was estimated that around 53.2 million people (21.2%), had been diagnosed with arthritis and rheumatoid arthritis in the United States, between 2019 to 2021.

Additionally, as per the data provided by the Centers for Disease Control and Prevention 2024, it was stated that around 38.4 million, accounting for 11.6% of the US population was suffering from diabetes, in 2021. Chronic diseases like diabetes and rheumatoid arthritis require continuous treatment over the long term. Patients need regular injections to manage their conditions, often for the rest of their lives. Prefilled syringes make these daily treatments easier, and more accurate, and allow easy self-administration of medications at home.

Furthermore, the well-established patient care system along with high awareness among patients and caregivers regarding different types of prefilled syringes is further expected to propel the United States prefilled syringes market growth.

Moreover, the increasing use of prefilled syringes highlights the rapid adoption of technologically advanced solutions, which is expected to drive market growth. For instance, in March 2024, Mallinckrodt plc. announced that the U.S. FDA approved the Acthar(R) Gel (repository corticotropin injection) Single-Dose SelfJect(TM) Injector, a new delivery device for Acthar Gel for patients with chronic and acute inflammatory and autoimmune conditions. The SelfJect was designed to allow patients greater control over their medication administration.

Thus, the above-mentioned factors are expected to escalate the market of prefilled syringes in the region.

Prefilled Syringes Market Key Players:

Some of the key market players operating in the Prefilled Syringes market include BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.

Recent Developmental Activities in the Prefilled Syringes Market:

  • In March 2024, SCHOTT Pharma expanded in the U.S. with a new prefillable syringe manufacturing facility in Wilson, North Carolina with a $371 million investment.
  • In May 2024, InvAscent, through India Life Sciences IV (ILSF IV), partnered with Morgan Stanley Private Equity Asia to invest INR 10,000 million in Maiva Pharma, recognized as India's second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds raised were intended to enhance vial, lyophilization, and suspension capacity, as well as to introduce new manufacturing capabilities, including prefilled syringes, cartridges, and bags.

Key Takeaways From the Prefilled Syringes Market Report Study

  • Market size analysis for current prefilled syringes size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the prefilled syringes market.
  • Various opportunities available for the other competitors in the prefilled syringes market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current prefilled syringes market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for prefilled syringes market growth in the coming future?

Target Audience Who Can be Benefited From This Prefilled Syringes Market Report Study

  • Prefilled syringes product providers
  • Research organizations and consulting companies
  • Prefilled syringes-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in prefilled syringes
  • Various end-users who want to know more about the prefilled syringes market and the latest technological developments in the prefilled syringes market.

Frequently Asked Questions for the Prefilled Syringes Market:

1. What are prefilled syringes?

  • Prefilled syringes are medical devices that deliver medication in precise, pre-measured doses, ready for immediate use. These syringes filled with liquid medication have a securely attached needle, ensuring safety and eliminating the need for preparation.

2. What is the market for prefilled syringes?

  • The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032.

3. What are the drivers for the global prefilled syringes market?

  • The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global prefilled syringes market?

  • Some of the key market players operating in the prefilled syringes are BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.

5. Which region has the highest share in the global prefilled syringes market?

  • North America region is anticipated to dominate the overall prefilled syringes market due to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key market players is further boosting the overall market of prefilled syringes across the region.

Table of Contents

1. Prefilled Syringes Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Prefilled Syringes Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Prefilled Syringes Market Key Factors Analysis

  • 5.1. Prefilled Syringes Market Drivers
    • 5.1.1. The increasing prevalence of chronic diseases
    • 5.1.2. Increase impact of biologics and biosimilar on prefilled syringes
    • 5.1.3. Increase adoption of self-administration across the globe
  • 5.2. Prefilled Syringes Market Restraints and Challenges
    • 5.2.1. Increasing product recalls and failures due to safety issues
    • 5.2.2. Availability of alternative products
  • 5.3. Prefilled Syringes Market Opportunities
    • 5.3.1. Increased funding and investment for more extensive research and development activities

6. Prefilled Syringes Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Prefilled Syringes Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Staked Needle System
    • 7.1.2. Luer Cone System
    • 7.1.3. Luer Lock System
  • 7.2. By Material
    • 7.2.1. Glass
    • 7.2.2. Plastic
  • 7.3. By Type
    • 7.3.1. With Needle
    • 7.3.2. Without Needle
  • 7.4. By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Online Pharmacies
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.1.2. Canada Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.1.3. Mexico Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.2. Germany Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.3. United Kingdom Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.4. Italy Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.5. Spain Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.2.6. Rest of Europe Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.2. Japan Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.3. India Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.4. Australia Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.5. South Korea Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific Prefilled Syringes Market Size in USD Million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.4.2. Africa Prefilled Syringes Market Size in USD Million (2022-2032)
      • 7.5.4.3. South America Prefilled Syringes Market Size in USD Million (2022-2032)

8. Prefilled Syringes Market Company and Product Profiles

  • 8.1. BD
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Nipro Corporation
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Taisei Kako Co., Ltd.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Terumo Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. SCHOTT Pharma AG & Co. KGaA
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Gerresheimer AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Johnson and Johnson Services, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Dali Medical Devices
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Stevanato Groupand
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Credence MedSystems, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Baxter
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. MAEDA INDUSTRY Co., Ltd.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. MedXL, Inc.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Sanofi
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Sandoz AG
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Pfizer Inc.
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. B. Braun Melsungen AG
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Novartis AG
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Fresenius SE & Co. KGaA
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Cardinal Health
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제